Dermatomyositis - Pipeline Insight, 2024

This “Dermatomyositis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dermatomyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dermatomyositis Understanding

Dermatomyositis: Overview

Dermatomyositis is a rare acquired immune-mediated muscle disease characterized by muscle weakness and skin rash. It is classified as one of the idiopathic inflammatory myopathies (IIM). Although all idiopathic inflammatory myopathies share the common presentation of muscle weakness, they differ clinically in terms of muscle groups involved and histopathological findings. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. Also, it can affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. A significant proportion of patients with dermatomyositis have an underlying malignancy, which can alter the prognosis of the condition. Although a majority of cases have muscular and cutaneous manifestations, other variants of the condition exist.

Dermatomyositis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dermatomyositis pipeline landscape is provided which includes the disease overview and Dermatomyositis treatment guidelines. The assessment part of the report embraces, in depth Dermatomyositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dermatomyositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Dermatomyositis R&D. The therapies under development are focused on novel approaches to treat/improve Dermatomyositis.

Dermatomyositis Emerging Drugs Chapters

This segment of the Dermatomyositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dermatomyositis Emerging Drugs

Lenabasum: Corbus PharmaceuticalsLenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has an acceptable safety and tolerability profiles without evidence of immunosuppression. Lenabasum is currently in phase III stage of development to treat Dermatomyositis.

KZR-616: Kezar Life SciencesKZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition. Playing a critical role in the body's immune system, the immunoproteasome is abundantly expressed in immune cells and acts as a master regulator of multiple cellular functions. By selectively inhibiting the immunoproteasome, KZR-616 has the potential to affect multiple drivers of immune-mediated diseases.

Dermatomyositis: Therapeutic Assessment

This segment of the report provides insights about the different Dermatomyositis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dermatomyositis

There are approx. 10+ key companies which are developing the therapies for Dermatomyositis. The companies which have their Dermatomyositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dermatomyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dermatomyositis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dermatomyositis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dermatomyositis drugs.

Dermatomyositis Report Insights

• Dermatomyositis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dermatomyositis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dermatomyositis drugs?
• How many Dermatomyositis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dermatomyositis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dermatomyositis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dermatomyositis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Corbus Pharmaceuticals
• Kezar Life Sciences
• Pfizer
• CSL Behring
• Viela Bio
• PAEAN Biotechnology
• Alexion Pharmaceuticals

Key Products

• Lenabasum
• KZR-616
• PF 06823859
• Hizentra
• Daxdilimab
• PN 101
• Ravulizumab

This product will be delivered within 1-3 business days.